BrainsWay’s (BWAY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of BrainsWay (NASDAQ:BWAY) in a report released on Monday, Benzinga reports. The firm currently has a $16.00 price objective on the stock.

Separately, Northland Securities upped their price objective on shares of BrainsWay from $9.00 to $11.00 and gave the company an outperform rating in a research note on Wednesday, August 7th.

BrainsWay Trading Up 1.4 %

NASDAQ BWAY opened at $8.40 on Monday. The business’s 50-day moving average price is $7.40 and its two-hundred day moving average price is $6.32. BrainsWay has a 12 month low of $3.09 and a 12 month high of $8.75. The firm has a market capitalization of $139.99 million, a PE ratio of -93.33 and a beta of 1.25.

BrainsWay (NASDAQ:BWAY) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter. The company had revenue of $10.01 million during the quarter, compared to the consensus estimate of $9.40 million. BrainsWay had a return on equity of 1.45% and a net margin of 1.67%. During the same period last year, the company earned ($0.05) earnings per share. As a group, analysts forecast that BrainsWay will post 0.06 earnings per share for the current fiscal year.

Institutional Trading of BrainsWay

Several large investors have recently modified their holdings of the stock. Essex Investment Management Co. LLC boosted its stake in BrainsWay by 37.5% during the first quarter. Essex Investment Management Co. LLC now owns 324,843 shares of the company’s stock worth $1,718,000 after acquiring an additional 88,593 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of BrainsWay by 48.1% during the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock worth $1,567,000 after purchasing an additional 84,371 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of BrainsWay in the 4th quarter valued at about $207,000. Perritt Capital Management Inc bought a new stake in BrainsWay in the 2nd quarter valued at about $121,000. Finally, Rhumbline Advisers increased its position in BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after buying an additional 1,695 shares in the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.